APO Research
Talk to an analyst

APO RESEARCH · REPORT

Solid Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Solid Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025190 pages

Choose your research edition.

Industry ResearchSolid Tumor Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Tumor Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Solid Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Tumor Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Tumor Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Solid Tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Solid Tumor Drug include Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc., Baxter, AstraZeneca, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Celgene Corporation and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Solid Tumor Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Solid Tumor Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Solid Tumor Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Solid Tumor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Solid Tumor Drug Segment by Company

Johnson & Johnson

Pfizer Inc

GlaxoSmithKline plc.

Baxter

AstraZeneca

F. Hoffmann-La Roche Ltd.

Eli Lilly and Company

Celgene Corporation

Bristol-Myers Squibb Company

Biogen

Amgen Limited & Amgen Ireland Limited

Abbott Laboratories

Solid Tumor Drug Segment by Type

Small Molecules

Biologics

Solid Tumor Drug Segment by Application

Radiology

Neurology

Oncology

Others

Solid Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Solid Tumor Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Solid Tumor Drug industry.

Chapter 3: Detailed analysis of Solid Tumor Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Solid Tumor Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Solid Tumor Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Small Molecules Table 3. Key Players of Biologics Table 4. Global Solid Tumor Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Radiology Table 6. Key Players of Neurology Table 7. Key Players of Oncology Table 8. Key Players of Others Table 9. Global Solid Tumor Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Solid Tumor Drug Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Solid Tumor Drug Market Share by Region (2021-2026) Table 12. Global Solid Tumor Drug Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Solid Tumor Drug Market Share by Region (2027-2032) Table 14. Solid Tumor Drug Industry Trends Table 15. Solid Tumor Drug Industry Drivers Table 16. Solid Tumor Drug Industry Opportunities and Challenges Table 17. Solid Tumor Drug Industry Restraints Table 18. Global Solid Tumor Drug Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Solid Tumor Drug Revenue Market Share by Company (2021-2026) Table 20. Global Solid Tumor Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Solid Tumor Drug Key Company Head Office and Area Served Table 22. Global Solid Tumor Drug Company, Product Type & Application Table 23. Global Solid Tumor Drug Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Solid Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Solid Tumor Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Solid Tumor Drug Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Solid Tumor Drug Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Solid Tumor Drug Revenue Market Share by Type (2021-2026) Table 30. Global Solid Tumor Drug Revenue Market Share by Type (2027-2032) Table 31. Global Solid Tumor Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Solid Tumor Drug Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Solid Tumor Drug Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Solid Tumor Drug Revenue Market Share by Application (2021-2026) Table 35. Global Solid Tumor Drug Revenue Market Share by Application (2027-2032) Table 36. Johnson & Johnson Company Information Table 37. Johnson & Johnson Business Overview Table 38. Johnson & Johnson Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Johnson & Johnson Solid Tumor Drug Product Portfolio Table 40. Johnson & Johnson Recent Development Table 41. Pfizer Inc Company Information Table 42. Pfizer Inc Business Overview Table 43. Pfizer Inc Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Pfizer Inc Solid Tumor Drug Product Portfolio Table 45. Pfizer Inc Recent Development Table 46. GlaxoSmithKline plc. Company Information Table 47. GlaxoSmithKline plc. Business Overview Table 48. GlaxoSmithKline plc. Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio Table 50. GlaxoSmithKline plc. Recent Development Table 51. Baxter Company Information Table 52. Baxter Business Overview Table 53. Baxter Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Baxter Solid Tumor Drug Product Portfolio Table 55. Baxter Recent Development Table 56. AstraZeneca Company Information Table 57. AstraZeneca Business Overview Table 58. AstraZeneca Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. AstraZeneca Solid Tumor Drug Product Portfolio Table 60. AstraZeneca Recent Development Table 61. F. Hoffmann-La Roche Ltd. Company Information Table 62. F. Hoffmann-La Roche Ltd. Business Overview Table 63. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio Table 65. F. Hoffmann-La Roche Ltd. Recent Development Table 66. Eli Lilly and Company Company Information Table 67. Eli Lilly and Company Business Overview Table 68. Eli Lilly and Company Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Eli Lilly and Company Solid Tumor Drug Product Portfolio Table 70. Eli Lilly and Company Recent Development Table 71. Celgene Corporation Company Information Table 72. Celgene Corporation Business Overview Table 73. Celgene Corporation Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Celgene Corporation Solid Tumor Drug Product Portfolio Table 75. Celgene Corporation Recent Development Table 76. Bristol-Myers Squibb Company Company Information Table 77. Bristol-Myers Squibb Company Business Overview Table 78. Bristol-Myers Squibb Company Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio Table 80. Bristol-Myers Squibb Company Recent Development Table 81. Biogen Company Information Table 82. Biogen Business Overview Table 83. Biogen Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Biogen Solid Tumor Drug Product Portfolio Table 85. Biogen Recent Development Table 86. Amgen Limited & Amgen Ireland Limited Company Information Table 87. Amgen Limited & Amgen Ireland Limited Business Overview Table 88. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio Table 90. Amgen Limited & Amgen Ireland Limited Recent Development Table 91. Abbott Laboratories Company Information Table 92. Abbott Laboratories Business Overview Table 93. Abbott Laboratories Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Abbott Laboratories Solid Tumor Drug Product Portfolio Table 95. Abbott Laboratories Recent Development Table 96. North America Solid Tumor Drug Market Size by Type (2021-2026) & (US$ Million) Table 97. North America Solid Tumor Drug Market Size by Type (2027-2032) & (US$ Million) Table 98. North America Solid Tumor Drug Market Size by Application (2021-2026) & (US$ Million) Table 99. North America Solid Tumor Drug Market Size by Application (2027-2032) & (US$ Million) Table 100. North America Solid Tumor Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Solid Tumor Drug Market Size by Country (2021-2026) Table 102. North America Solid Tumor Drug Market Size by Country (2027-2032) Table 103. Europe Solid Tumor Drug Market Size by Type (2021-2026) & (US$ Million) Table 104. Europe Solid Tumor Drug Market Size by Type (2027-2032) & (US$ Million) Table 105. Europe Solid Tumor Drug Market Size by Application (2021-2026) & (US$ Million) Table 106. Europe Solid Tumor Drug Market Size by Application (2027-2032) & (US$ Million) Table 107. Europe Solid Tumor Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Solid Tumor Drug Market Size by Country (2021-2026) Table 109. Europe Solid Tumor Drug Market Size by Country (2027-2032) Table 110. China Solid Tumor Drug Market Size by Type (2021-2026) & (US$ Million) Table 111. China Solid Tumor Drug Market Size by Type (2027-2032) & (US$ Million) Table 112. China Solid Tumor Drug Market Size by Application (2021-2026) & (US$ Million) Table 113. China Solid Tumor Drug Market Size by Application (2027-2032) & (US$ Million) Table 114. Asia Solid Tumor Drug Market Size by Type (2021-2026) & (US$ Million) Table 115. Asia Solid Tumor Drug Market Size by Type (2027-2032) & (US$ Million) Table 116. Asia Solid Tumor Drug Market Size by Application (2021-2026) & (US$ Million) Table 117. Asia Solid Tumor Drug Market Size by Application (2027-2032) & (US$ Million) Table 118. Asia Solid Tumor Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Solid Tumor Drug Market Size by Country (2021-2026) Table 120. Asia Solid Tumor Drug Market Size by Country (2027-2032) Table 121. South America, Middle East & Africa Solid Tumor Drug Market Size by Type (2021-2026) & (US$ Million) Table 122. South America, Middle East & Africa Solid Tumor Drug Market Size by Type (2027-2032) & (US$ Million) Table 123. South America, Middle East & Africa Solid Tumor Drug Market Size by Application (2021-2026) & (US$ Million) Table 124. South America, Middle East & Africa Solid Tumor Drug Market Size by Application (2027-2032) & (US$ Million) Table 125. South America, Middle East & Africa Solid Tumor Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. South America, Middle East & Africa Solid Tumor Drug Market Size by Country (2021-2026) Table 127. South America, Middle East & Africa Solid Tumor Drug Market Size by Country (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Solid Tumor Drug Product Image Figure 2. Global Solid Tumor Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Solid Tumor Drug Market Share by Type: 2025 VS 2032 Figure 4. Small Molecules Image Figure 5. Biologics Image Figure 6. Global Solid Tumor Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Solid Tumor Drug Market Share by Application: 2025 VS 2032 Figure 8. Radiology Image Figure 9. Neurology Image Figure 10. Oncology Image Figure 11. Others Image Figure 12. Global Solid Tumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 14. Global Solid Tumor Drug Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Solid Tumor Drug Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Solid Tumor Drug Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Solid Tumor Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Solid Tumor Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Solid Tumor Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Solid Tumor Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 24. North America Solid Tumor Drug Market Share by Type (2021-2032) Figure 25. North America Solid Tumor Drug Market Share by Application (2021-2032) Figure 26. North America Solid Tumor Drug Market Share by Country (2021-2032) Figure 27. United States Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 28. Canada Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 30. Europe Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 31. Europe Solid Tumor Drug Market Share by Type (2021-2032) Figure 32. Europe Solid Tumor Drug Market Share by Application (2021-2032) Figure 33. Europe Solid Tumor Drug Market Share by Country (2021-2032) Figure 34. Germany Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 35. France Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 37. Italy Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 38. Russia Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 40. China Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 41. China Solid Tumor Drug Market Share by Type (2021-2032) Figure 42. China Solid Tumor Drug Market Share by Application (2021-2032) Figure 43. Asia Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 44. Asia Solid Tumor Drug Market Share by Type (2021-2032) Figure 45. Asia Solid Tumor Drug Market Share by Application (2021-2032) Figure 46. Asia Solid Tumor Drug Market Share by Country (2021-2032) Figure 47. Japan Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 51. India Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 52. Australia Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Solid Tumor Drug Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Solid Tumor Drug Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Solid Tumor Drug Market Share by Country (2021-2032) Figure 57. Brazil Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 62. UAE Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 64. Chile Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecules
  • Biologics
Applications
  • Radiology
  • Neurology
  • Oncology
  • Others
Companies covered
  • Johnson & Johnson
  • Pfizer Inc
  • GlaxoSmithKline plc.
  • Baxter
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • Biogen
  • Amgen Limited & Amgen Ireland Limited
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Solid Tumor Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Small Molecules
  5. 1.2.3 Biologics
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Solid Tumor Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Radiology
  9. 1.3.3 Neurology
  10. 1.3.4 Oncology
  11. 1.3.5 Others
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Solid Tumor Drug Growth Trends by Region
  14. 1.5.1 Global Solid Tumor Drug Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Solid Tumor Drug Market Size by Region (2021-2026)
  16. 1.5.3 Solid Tumor Drug Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Solid Tumor Drug Market Dynamics
  1. 2.1 Solid Tumor Drug Industry Trends
  2. 2.2 Solid Tumor Drug Industry Drivers
  3. 2.3 Solid Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Solid Tumor Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Solid Tumor Drug Revenue by Company (2021-2026)
  2. 3.2 Global Solid Tumor Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Solid Tumor Drug Key Company Head office and Area Served
  4. 3.4 Global Solid Tumor Drug Company, Product Type & Application
  5. 3.5 Global Solid Tumor Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Solid Tumor Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Solid Tumor Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Solid Tumor Drug Tier 1, Tier 2, and Tier 3
4 Solid Tumor Drug Market by Type
  1. 4.1 Global Solid Tumor Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Solid Tumor Drug Market Size by Type (2021-2032)
  3. 4.3 Global Solid Tumor Drug Market Size Share by Type (2021-2032)
5 Solid Tumor Drug Market by Application
  1. 5.1 Global Solid Tumor Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Solid Tumor Drug Market Size by Application (2021-2032)
  3. 5.3 Global Solid Tumor Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Johnson & Johnson
  2. 6.1.1 Johnson & Johnson Company Information
  3. 6.1.2 Johnson & Johnson Business Overview
  4. 6.1.3 Johnson & Johnson Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Johnson & Johnson Solid Tumor Drug Product Portfolio
  6. 6.1.5 Johnson & Johnson Recent Developments
  7. 6.2 Pfizer Inc
  8. 6.2.1 Pfizer Inc Company Information
  9. 6.2.2 Pfizer Inc Business Overview
  10. 6.2.3 Pfizer Inc Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Pfizer Inc Solid Tumor Drug Product Portfolio
  12. 6.2.5 Pfizer Inc Recent Developments
  13. 6.3 GlaxoSmithKline plc.
  14. 6.3.1 GlaxoSmithKline plc. Company Information
  15. 6.3.2 GlaxoSmithKline plc. Business Overview
  16. 6.3.3 GlaxoSmithKline plc. Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio
  18. 6.3.5 GlaxoSmithKline plc. Recent Developments
  19. 6.4 Baxter
  20. 6.4.1 Baxter Company Information
  21. 6.4.2 Baxter Business Overview
  22. 6.4.3 Baxter Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Baxter Solid Tumor Drug Product Portfolio
  24. 6.4.5 Baxter Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 AstraZeneca Solid Tumor Drug Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 F. Hoffmann-La Roche Ltd.
  32. 6.6.1 F. Hoffmann-La Roche Ltd. Company Information
  33. 6.6.2 F. Hoffmann-La Roche Ltd. Business Overview
  34. 6.6.3 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio
  36. 6.6.5 F. Hoffmann-La Roche Ltd. Recent Developments
  37. 6.7 Eli Lilly and Company
  38. 6.7.1 Eli Lilly and Company Company Information
  39. 6.7.2 Eli Lilly and Company Business Overview
  40. 6.7.3 Eli Lilly and Company Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Eli Lilly and Company Solid Tumor Drug Product Portfolio
  42. 6.7.5 Eli Lilly and Company Recent Developments
  43. 6.8 Celgene Corporation
  44. 6.8.1 Celgene Corporation Company Information
  45. 6.8.2 Celgene Corporation Business Overview
  46. 6.8.3 Celgene Corporation Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Celgene Corporation Solid Tumor Drug Product Portfolio
  48. 6.8.5 Celgene Corporation Recent Developments
  49. 6.9 Bristol-Myers Squibb Company
  50. 6.9.1 Bristol-Myers Squibb Company Company Information
  51. 6.9.2 Bristol-Myers Squibb Company Business Overview
  52. 6.9.3 Bristol-Myers Squibb Company Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio
  54. 6.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 6.10 Biogen
  56. 6.10.1 Biogen Company Information
  57. 6.10.2 Biogen Business Overview
  58. 6.10.3 Biogen Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Biogen Solid Tumor Drug Product Portfolio
  60. 6.10.5 Biogen Recent Developments
  61. 6.11 Amgen Limited & Amgen Ireland Limited
  62. 6.11.1 Amgen Limited & Amgen Ireland Limited Company Information
  63. 6.11.2 Amgen Limited & Amgen Ireland Limited Business Overview
  64. 6.11.3 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio
  66. 6.11.5 Amgen Limited & Amgen Ireland Limited Recent Developments
  67. 6.12 Abbott Laboratories
  68. 6.12.1 Abbott Laboratories Company Information
  69. 6.12.2 Abbott Laboratories Business Overview
  70. 6.12.3 Abbott Laboratories Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Abbott Laboratories Solid Tumor Drug Product Portfolio
  72. 6.12.5 Abbott Laboratories Recent Developments
7 North America
  1. 7.1 North America Solid Tumor Drug Market Size (2021-2032)
  2. 7.2 North America Solid Tumor Drug Market Size by Type
  3. 7.2.1 North America Solid Tumor Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Solid Tumor Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Solid Tumor Drug Market Share by Type (2021-2032)
  6. 7.3 North America Solid Tumor Drug Market Size by Application
  7. 7.3.1 North America Solid Tumor Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Solid Tumor Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Solid Tumor Drug Market Share by Application (2021-2032)
  10. 7.4 North America Solid Tumor Drug Market Size by Country
  11. 7.4.1 North America Solid Tumor Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Solid Tumor Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Solid Tumor Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Solid Tumor Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Solid Tumor Drug Market Size (2021-2032)
  2. 8.2 Europe Solid Tumor Drug Market Size by Type
  3. 8.2.1 Europe Solid Tumor Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Solid Tumor Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Solid Tumor Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Solid Tumor Drug Market Size by Application
  7. 8.3.1 Europe Solid Tumor Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Solid Tumor Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Solid Tumor Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Solid Tumor Drug Market Size by Country
  11. 8.4.1 Europe Solid Tumor Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Solid Tumor Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Solid Tumor Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Solid Tumor Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Solid Tumor Drug Market Size (2021-2032)
  2. 9.2 China Solid Tumor Drug Market Size by Type
  3. 9.2.1 China Solid Tumor Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Solid Tumor Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Solid Tumor Drug Market Share by Type (2021-2032)
  6. 9.3 China Solid Tumor Drug Market Size by Application
  7. 9.3.1 China Solid Tumor Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Solid Tumor Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Solid Tumor Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Solid Tumor Drug Market Size (2021-2032)
  2. 10.2 Asia Solid Tumor Drug Market Size by Type
  3. 10.2.1 Asia Solid Tumor Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Solid Tumor Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Solid Tumor Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Solid Tumor Drug Market Size by Application
  7. 10.3.1 Asia Solid Tumor Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Solid Tumor Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Solid Tumor Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Solid Tumor Drug Market Size by Country
  11. 10.4.1 Asia Solid Tumor Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Solid Tumor Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Solid Tumor Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Solid Tumor Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Solid Tumor Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Solid Tumor Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Solid Tumor Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Solid Tumor Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Solid Tumor Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Solid Tumor Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Solid Tumor Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Solid Tumor Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Solid Tumor Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Solid Tumor Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Solid Tumor Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Solid Tumor Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Solid Tumor Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Solid Tumor Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst